Are anthracyclines needed for the neoadjuvant treatment of patients with HER2-positive early breast cancer?

Jagiełło-Gruszfeld, Agnieszka; Pogoda, Katarzyna; Niwińska, Anna; Lemańska, I.; Szombara, Ewa; Górniak, Anna; Jagielska, Beata; Nowecki, Zbigniew

doi:10.1200/jco.2018.36.15_suppl.e12599

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A document by the Department of Breast Cancer & Reconstructive Surgery of the National Research Institute of Oncology confirmed especially high rate of pathological complete remissions achieved in patients included in TCH-regimen neoadjuvant therapy (docetaxel, carboplatin, trastuzumab) -55% in the group of patients with cancers of 10-50 mm, cN0 or cN1 (while pCR rate in the subgroup of patients with non-luminal HER2-positive cancers was 66%). Meanwhile, in a cohort of patients included in the TCH-P regimen (doctaxel, carboplatin, trastuzumab, pertuzumab), pCR rate was 76% (while in the group of patients with non-luminal, HER2-positive cancers, pCR as high as 87% was observed, especially for less advanced cancers), which will probably affect distant results of the treatment [16,17] trastuzumab and carboplatin (TCH.…”

Section: Systemic Treatmentmentioning

confidence: 99%

Leczenie przedoperacyjne chorych na raka piersi i jego wpływ na postępowanie operacyjne oraz radioterapeutyczne. Część 1.

Nowecki

Jagiełło-Gruszfeld

Pogoda

et al. 2021

Nowotwory. Journal of Oncology

Self Cite

View full text Add to dashboard Cite

Neoadjuvant therapy (NAT) is increasingly applied in patients with initially inoperable breast cancers and, frequently, in those with tumours that are initially operable, too. In most cases, the response to the applied NAT affects the scope of surgical treatment and radiotherapy, and in some situations also the complementary systemic postoperative treatment. The available studies indicate importance of response to NAT within the breast and regional lymph nodes. Assessment of response to treatment allows personalization of treatment and in some cases a change of therapy, which improves long-term outcomes. This article summarizes the current rules of conduct in patients with early breast cancer qualified for neoadjuvant therapy, paying attention to the practical aspects and possibilities of national health insurance-covered therapies in Poland. It discusses in detail the applied regimens of systemic therapy, surgical techniques, eligibility rules and complementary radiotherapy. Systems for assessing response to neoadjuvant treatment are also presented.

show abstract

Section: Systemic Treatmentmentioning

confidence: 99%

Leczenie przedoperacyjne chorych na raka piersi i jego wpływ na postępowanie operacyjne oraz radioterapeutyczne. Część 1.

Nowecki

Jagiełło-Gruszfeld

Pogoda

et al. 2021

Nowotwory. Journal of Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Personalization of BC therapy improves outcomes and reduces costs and toxicity [10,11]. In earlier studies from our department PCR was archived in 55%-87% patients with HER2-NL and HER2-LB who received TCH (docetaxel, carboplatin, trastuzumab) and TCH+P (docetaxel, carboplatin, trastuzumab + pertuzumab) NAT regimens [12,13]. Despite the signi cant advances in recent years, treatment results are still not satisfactory, and it is unknown why some patients with the same cancer subtype bene t from treatment and others do not.…”

Section: Introductionmentioning

confidence: 99%

Predictive Value of Serum Aurora A, Thymidine Kinase 1, and HER3/ErbB3 in Breast Cancer Patients Before Neoadjuvant Treatment

Winter

Kotowicz

Fuksiewicz

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Further personalization is needed to improve the outcomes of breast cancer treatment. It is necessary to find new inexpensive and easily evaluated predictive markers. In this study, we determined serum level of Aurora A (AURKA), thymidine kinase 1 (TK1) and human epidermal growth factor receptor type 3 (HER3) by enzyme immunoassay ELISA. We collected peripheral blood sera of 119 women with breast cancer before neoadjuvant treatment and the control group of 47 randomly selected healthy women. After treatment we analyzed clinical data: age, initial TNM stage, tumor receptors expression: estrogen (ER), progesterone (PGR), epidermal growth factor receptor type 2 (HER2), Ki67, histological malignancy grade, biological subtype, and response to neoadjuvant treatment in residual cancer burden (RCB) classification. Pathologic complete response (PCR) was achieved in 41 patients (34.45%). In univariate analysis patients with higher AURKA levels were more likely to obtain PCR (p=0.039). In multivariate analysis we used the logit regression model with PCR as the dependent. The effect of AURKA concentration ≥4.75 ng / mL on the chance of achieving PCR was found (OR: 3.5; 95%CI: 1.2-10.1; p = 0.023). Other significant PCR factors included: node status (OR: 0.503; 95% CI: 0.263-0.965; p = 0.039), negative PGR expression (OR: 0.104; 95% CI: 0.038-0.284; p < 0.001), and Ki67 >20% (OR: 5.44; 95% CI: 1.24-23,9; p < 0.025). There was no significance in marker concentrations and clinical features nor between breast cancer patients and control group. The outcomes suggest that serum AURKA level is a potential PCR prediction marker in neoadjuvant breast cancer treatment. Further studies are needed to confirm our observations.

show abstract

Are anthracyclines needed for the neoadjuvant treatment of patients with HER2-positive early breast cancer?

Cited by 2 publications

References 0 publications

Leczenie przedoperacyjne chorych na raka piersi i jego wpływ na postępowanie operacyjne oraz radioterapeutyczne. Część 1.

Leczenie przedoperacyjne chorych na raka piersi i jego wpływ na postępowanie operacyjne oraz radioterapeutyczne. Część 1.

Predictive Value of Serum Aurora A, Thymidine Kinase 1, and HER3/ErbB3 in Breast Cancer Patients Before Neoadjuvant Treatment

Contact Info

Product

Resources

About